

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7187555

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD	02/18/2022
RECEIVING PARTY DATA	
Name:	NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
Street Address:	ROOM 1305-1307, SINO-DANNISH BUILDING B
Internal Address:	NO. 3-1 XINJINHU ROAD, JIANGBEI NEW AREA
City:	NANJING, JIANGSU
State/Country:	CHINA
Postal Code:	210032
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	10792283
Application Number:	17004734
Application Number:	62304148
CORRESPONDENCE DATA	
Fax Number:	(415)268-7522
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4152687000
Email:	JRitter@mofo.com
Correspondent Name:	WEI TANG
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	425 MARKET STREET
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105
ATTORNEY DOCKET NUMBER:	19602-28001.00
NAME OF SUBMITTER:	WEI TANG
SIGNATURE:	/Wei Tang/
DATE SIGNED:	02/22/2022
Total Attachments: 3	
source=19602-28001.00 Assignment#page1.tif	
source=19602-28001.00 Assignment#page2.tif	

ASSIGNMENT

This Assignment is by:

Assignor: HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD.
Address: Room A0101, Building 2, Baiyangjiedao
No 6 BLVD, HEDA
Hangzhou
Zhejiang 310018
A juristic entity duly organized under and pursuant to the laws of: CHINA

(referred to in this Assignment as “Assignor”), which is the sole and exclusive owner, by assignment, of the patents and patent applications identified in **Appendix A** appended hereto.

This Assignment is to:

Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
Address: Sino-Dannish Ecolife, Science Industrial Park-NJBPV
No.3-1 Xinjinhu Road,
Nanjing, Jiangsu 210032 CHINA
A juristic entity duly organized under and pursuant to the laws of: CHINA

(referred to in this Assignment as “Assignee”), which desires to acquire the entire right, title and interest in, to and under said patents and patent applications in Appendix A and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement.

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor’s entire right, title and interest in and to the above-mentioned inventions, patents, applications for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

3. Assignor hereby grants Assignee’s attorneys, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 2/18/2022

Signature: 
Name: Hao, Xiaolin
Title: CEO
Company: Hangzhou Zhengxiang Pharmaceuticals
Co., Ltd.

ASSIGNEE:

Date: 2/18/2022

Signature: 
Name: Hao, Xiaolin
Title: CEO
Company: Nanjing Zhengxiang Pharmaceuticals
Co., LTD.

APPENDIX A

All dates in month/date/year format

No.	Country	Application No.	Filing Date	Patent No.	Issue Date
1.	Patent Cooperation Treaty	PCT/US2017/019970	February 28, 2017		
2.	Canada	3013490	February 28, 2017	3013490	September 14, 2021
3.	Canada	3124815	February 28, 2017		
4.	China	201780004233.0	February 28, 2017	108290898	September 8, 2020
5.	China	202011068570.6	February 28, 2017		
6.	Europe	17763752.7	February 28, 2017	3400227	March 31, 2021
7.	France	17763752.7	February 28, 2017	3400227	March 31, 2021
8.	Germany	60 2017 035 763.4	February 28, 2017	60 2017 035 763.4	March 31, 2021
9.	Italy	502021000046253	February 28, 2017	502021000046253	March 31, 2021
10.	Netherlands	17763752.7	February 28, 2017	3400227	March 31, 2021
11.	Spain	17763752.7	February 28, 2017	3400227	March 31, 2021
12.	Switzerland	17763752.7	February 28, 2017	3400227	March 31, 2021
13.	United Kingdom	17763752.7	February 28, 2017	3400227	March 31, 2021
14.	Japan	2018-533215	February 28, 2017		
15.	Republic of Korea	10-2018-7025588	February 28, 2017	10-2256497	May 20, 2021
16.	Republic of Korea	10-2021-7014690	February 28, 2017		
17.	United States	16/072,150	February 28, 2017	10,792,283	October 6, 2020
18.	United States	17/004,734	August 27, 2020		
19.	United States	62/304,148	March 5, 2016		